Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001342
Filing Date
2025-05-15
Accepted
2025-05-15 17:00:50
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrkr-20250331x10q.htm   iXBRL 10-Q 942559
2 EX-31.1 mrkr-20250331xex31d1.htm EX-31.1 12180
3 EX-31.2 mrkr-20250331xex31d2.htm EX-31.2 12335
4 EX-32.1 mrkr-20250331xex32d1.htm EX-32.1 6780
5 EX-32.2 mrkr-20250331xex32d2.htm EX-32.2 6938
6 GRAPHIC mrkr-20250331x10q001.jpg GRAPHIC 9657
7 GRAPHIC mrkr-20250331x10q002.jpg GRAPHIC 42259
8 GRAPHIC mrkr-20250331x10q003.jpg GRAPHIC 34707
  Complete submission text file 0001410578-25-001342.txt   4732905

Data Files

Seq Description Document Type Size
9 EX-101.SCH mrkr-20250331.xsd EX-101.SCH 41252
10 EX-101.CAL mrkr-20250331_cal.xml EX-101.CAL 22241
11 EX-101.DEF mrkr-20250331_def.xml EX-101.DEF 152017
12 EX-101.LAB mrkr-20250331_lab.xml EX-101.LAB 309118
13 EX-101.PRE mrkr-20250331_pre.xml EX-101.PRE 232933
67 EXTRACTED XBRL INSTANCE DOCUMENT mrkr-20250331x10q_htm.xml XML 627289
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37939 | Film No.: 25955121
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)